Approval Makes Xiidra The Apple Of Shire's Eye

Jul. 13, 2016 9:46 AM ETShire PLC (SHPG), SHPGF2 Comments
EP Vantage profile picture
EP Vantage

The FDA go-ahead for Shire’s (NASDAQ:SHPG) (OTCPK:SHPGF) dry eye drug Xiidra is not only a relief after a checkered path to approval, but should also help the group reduce its reliance on its ADHD franchise. Xiidra is easily the company’s most valuable pipeline asset and is expected to be Shire’s second biggest seller in 2022 behind ADHD drug Vyvanse (see table below).

To get there, Xiidra will need to capture market share from Allergan’s (AGN) Restasis – which might not be too difficult, as Xiidra’s label cites a quicker onset of action and the fact it can treat both the signs and symptoms of dry eye disease. Restasis, meanwhile, is only approved to treat the signs.

Shire has not yet given pricing details but Leerink analysts expect Xiidra to cost about the same as Restasis, at around $300 per prescription, while Evercore ISI’s Umer Raffat believes a premium could be justified.

How well Shire does at luring away Allergan’s customers could depend on its pricing strategy: Xiidra will benefit from a better label, but payers might still prefer Restasis if it is much cheaper.

Shire’s top-five products in 2022




2022e sales ($m)






Dry eye




Hereditary angioedema

Phase III



Hereditary angioedema




Hunter syndrome



According to EvaluatePharma consensus

But the drug could also appeal to more patients, with Leerink saying the treatable patient population could number nine million versus the one million currently using Restasis. And the overall market is even bigger: Mr Raffat noted that around 54 million people in the US suffer from dry eye disease, and that around 16 million are seeking treatment.

Dry your eyes mate

The decision is a turnaround for Shire, which

This article was written by

EP Vantage profile picture
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.